---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015494"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:41:44.788636+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma Q1 net loss $24M; cash $94.4M funds ops into Q2 2024; WHIM NDA on track

## Summary
- Cash, cash equivalents, and restricted cash of $94.4M as of March 31, 2023, sufficient into Q2 2024.
- R&D expenses $22.1M (up from $14.1M YoY) including $5.0M accrual for probable in-licensing milestone.
- Net loss $24.0M vs $22.0M YoY; includes $1.6M stock compensation and $5.4M gain on warrant liability.
- U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half 2023.
- Phase 2 chronic neutropenia data and regulatory path update anticipated in Q2/Q3 2023.

## SEC filing metadata
- accession: 0001628280-23-015494
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/0001628280-23-015494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/xfor-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015494
- JSON: https://secwatch.observer/filing/0001628280-23-015494.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015494.txt

## Key facts
- Earnings Releases
  X4 Pharmaceuticals, Inc reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: X4 Pharmaceuticals Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/0001628280-23-015494-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.